

Regulated Information - Transparency Statement

Mr Thomas M. Clay and Mrs Lavinia Clay: control and voting rights Oxurion NV

Leuven, Belgium, 10 May 2019 – Pursuant to Belgian transparency legislation (Law of 2 May 2007), Oxurion NV (Euronext Brussels: OXUR) received transparency notifications on 30 April 2019 from Mr. Thomas M. Clay and his controlled entities (Landon T. Clay 2017-1 Annuity Trust, Estate of Landon T. Clay, East Hill Hedge Fund LLC, Monadnock Charitable Lead Annuity Trust, Clay Fellowships Charitable Trust and The Clay Mathematics Institute, Inc.) and from Mrs. Lavinia D. Clay.

As of 1 May 2019, Mrs. Lavinia D. Clay, the East Hill Hedge Fund, LLC, and the Monadnock Charitable Lead Annuity Trust entered into an investment advisor agreement with Epacria Capital Partners, LLC, in which Mr Thomas M. Clay has complete authority on a discretionary base over the voting rights related to the Oxurion shares of Mrs. Lavinia D. Clay, the Monadnock Charitable Lead Annuity Trust, and the East Hill Hedge Fund, LLC.

As a result, the voting percentage of Thomas M. Clay is now 8.78%, representing 3,361,555 of the current 38,291,950 outstanding Oxurion shares.

On 2 May 2019, based on all received transparency declarations received, Oxurion NV is aware of the following participations:

Shareholder	# of securities	% of voting rights
Mr Thomas M. Clay and entities controlled by him	3,361,555	8.78%
Baron Philippe Vlerick and entities controlled by him	2,324,719	6.07%
Novartis Pharma AG	2,177,226	5.69%

END

For further information please contact:

<u>Oxurion NV</u> Wouter Piepers, Global Head of Investor Relations & Corp Coms +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com	
EU - Citigate Dewe Rogerson David Dible/ Sylvie Berrebi Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com	US - LifeSci Public Relations Alison Chen +1 646-876-4932 achen@lifescipublicrelations.com

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company focused on transforming treatments to preserve vision in patients with diseases affecting the back of the eye. The company is currently developing a competitive pipeline of disease-modifying drug candidates for diabetic eye disease, a leading cause of blindness of people of working age worldwide.

Oxurion's most advanced drug candidate is THR-317, a PIGF inhibitor for the treatment of diabetic macular edema (DME), which is currently in a Phase 2 study in combination with Lucentis[®]. THR-317 is also being evaluated in a Phase 2 study for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1), a rare retinal disease that affects the macula and can lead to vision loss.

Oxurion has two further pipeline candidates, THR-149, a plasma kallikrein inhibitor being developed for the treatment of DME; and THR-687, a pan-RGD integrin antagonist in development for the treatment of diabetic retinopathy and DME. Both THR-149 and THR-687 are in Phase 1 clinical studies.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.